Literature DB >> 9507919

Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications.

A J Anwar1, J D Walker, B M Frier.   

Abstract

Type 1 insulin-dependent, diabetes mellitus (Type 1 DM) is thought to be more prevalent in individuals with Down's syndrome. To ascertain the local prevalence of Type 1 DM in patients with Down's syndrome in a geographically defined area, the four diabetes clinics in Lothian were surveyed and 13 patients with Down's syndrome and Type 1 DM were identified. Using data from previous epidemiological surveys which determined the prevalence of Down's syndrome in the general population, the prevalence rate of Type 1 DM in patients with Down's syndrome was calculated to be between 1.4 and 10.6%, a prevalence considerably higher than in the general population. Although 7 (54%) of the Down's syndrome patients were treated with once daily administration of insulin, the mean HbA1c value of the group was similar to that observed in a control group of 39 age-, sex- and duration-matched Type 1 patients, all of whom were taking two or more injections of insulin daily. Glycaemic control was therefore of similar quality to matched Type 1 patients without Down's syndrome, despite the frequent use of simple insulin regimens, which may relate to the more stable lifestyle of these patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9507919     DOI: 10.1002/(SICI)1096-9136(199802)15:2<160::AID-DIA537>3.0.CO;2-J

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  40 in total

Review 1.  An overview and update regarding medical problems in Down syndrome.

Authors:  V Grech
Journal:  Indian J Pediatr       Date:  2001-09       Impact factor: 1.967

2.  Down syndrome: is it really characterized by precocious immunosenescence?

Authors:  Maaike Aa Kusters; Ruud Hj Verstegen; Esther de Vries
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

3.  High prevalence of diabetes and pre-diabetes in adults with Williams syndrome.

Authors:  B R Pober; E Wang; S Caprio; K F Petersen; C Brandt; T Stanley; L R Osborne; J Dzuria; B Gulanski
Journal:  Am J Med Genet C Semin Med Genet       Date:  2010-05-15       Impact factor: 3.908

4.  Health conditions associated with aging and end of life of adults with Down syndrome.

Authors:  Anna J Esbensen
Journal:  Int Rev Res Ment Retard       Date:  2010

5.  Increased prevalence of Down's syndrome in individuals with type 1 diabetes in Denmark: A nationwide population-based study.

Authors:  R Bergholdt; S Eising; J Nerup; F Pociot
Journal:  Diabetologia       Date:  2006-03-31       Impact factor: 10.122

Review 6.  Genome-wide association studies in type 1 diabetes.

Authors:  Struan F A Grant; Hakon Hakonarson
Journal:  Curr Diab Rep       Date:  2009-04       Impact factor: 4.810

7.  Down's syndrome in diabetic patients aged <20 years: an analysis of metabolic status, glycaemic control and autoimmunity in comparison with type 1 diabetes.

Authors:  T R Rohrer; P Hennes; A Thon; A Dost; M Grabert; B Rami; S Wiegand; R W Holl
Journal:  Diabetologia       Date:  2010-02-26       Impact factor: 10.122

8.  Co-expression network analysis of Down's syndrome based on microarray data.

Authors:  Jianping Zhao; Zhengguo Zhang; Shumin Ren; Yanan Zong; Xiangdong Kong
Journal:  Exp Ther Med       Date:  2016-06-17       Impact factor: 2.447

9.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

10.  Immune-related conditions and acute leukemia in children with Down syndrome: a Children's Oncology Group report.

Authors:  Amy M Linabery; Wenchao Li; Michelle A Roesler; Logan G Spector; Alan S Gamis; Andrew F Olshan; Nyla A Heerema; Julie A Ross
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12-10       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.